Halozyme Therapeutics, INC 8-K filings

Halozyme Therapeutics announced a 34% year-over-year increase in total revenue and a 67% increase in net income for the third quarter of 2024, leading to an increased financial outlook for the year.

Halozyme announced robust second quarter 2024 financial results, highlighted by a 12% year-over-year increase in royalty revenue and a net income of $93 million.

Halozyme Therapeutics announced a 21% year-over-year increase in revenue to $196 million for the first quarter of 2024, alongside a new $750 million share repurchase program.

Halozyme Therapeutics held its annual meeting, electing two Class II directors, approving executive compensation, amending its certificate of incorporation, and ratifying its accounting firm.

Halozyme Therapeutics reported a 27% year-over-year increase in fourth-quarter revenue and announced a new $750 million share repurchase program, while reiterating its 2024 financial guidance.

Halozyme Therapeutics estimates its 2023 revenue to be between $827 million and $832 million, with net income between $292 million and $297 million.